Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Trial Profile

Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Crizotinib (Primary) ; Itraconazole; Rifampicin
  • Indications Anaplastic large cell lymphoma; Cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms PROFILE-1001
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2017 According to a Pfizer Canada media release, health Canada has expanded the indication of XALKORI (crizotinib) to include its use as a monotherapy in the treatment of patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC), based on data from this trial.
    • 18 Oct 2017 Results (n=52) assessing plasma genomic profiling and clinical outcomes in patients with Met Exon 14-Altered non small cell lung cancer, presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results of analysis assessing the effect of dexamethasone on steady-state crizotinib exposure using patient data from PROFILE-1001, PROFILE-1005, PROFILE-1007, PROFILE-1014 trials presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top